Trazodone Hydrochloride: The Definitive Guide
What is trazodone?
Trazodone is a triazolopyridine-derivative antidepressant that belongs to the serotonin antagonist and reuptake inhibitor (SARI) class.
It was approved by the U.S. Food and Drug Administration (FDA) in 1981 for the treatment of major depressive disorder (MDD) in adults.
Today, it is sold under brand names such as Desyrel® and Oleptro® (an extended-release formulation), though generic trazodone hydrochloride tablets are widely available.
Unlike older tricyclic antidepressants (TCAs) or widely used selective serotonin reuptake inhibitors (SSRIs), trazodone has a unique dual mechanism: it inhibits the serotonin transporter while simultaneously blocking specific serotonin receptors.
The double action is what makes it both an effective antidepressant and, at lower doses, one of the most commonly prescribed off-label sleep aids in the country.
In fact, a 2018 study found that 33% of patients prescribed a sleep aid received trazodone.
Trazodone is often described as a “multimodal” antidepressant because it influences several neurotransmitter systems beyond serotonin.
It also blocks histamine H1 receptors (contributing to its sedative effects) and α1-adrenergic receptors (which can lead to orthostatic hypotension).
Importantly, trazodone lacks significant anticholinergic activity, meaning it does not cause the dry mouth, constipation, or cognitive fog that plague many older antidepressants.
The favorable side-effect profile has made it particularly popular in geriatric medicine, where anticholinergic burden is a major concern.
Is trazodone a controlled substance?
No—trazodone is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or the FDA.
It does not appear in any DEA drug schedule (I–V) because clinical trials have not demonstrated abuse potential or drug-seeking behavior.
The FDA’s official labeling for trazodone explicitly states that “no indication of drug-seeking behavior was seen in clinical trials”.
Despite this clear regulatory status, some confusion persists. Trazodone is sometimes mentioned in the same breath as benzodiazepines or “Z-drugs” (zolpidem, eszopiclone) because of its sedating properties and its popularity as an off-label sleep aid.
However, unlike benzodiazepines, trazodone does not bind to GABA receptors and does not produce the euphoria or rapid tolerance that drives addiction.
While some recent large-scale research has raised theoretical concerns about its abuse potential in specific populations, the consensus among regulatory bodies and clinical guidelines remains that trazodone is not a controlled substance.
It’s worth noting that trazodone is also not a narcotic.
Narcotics are opioids—drugs that relieve pain by binding to opioid receptors in the brain.
Trazodone is an antidepressant that modulates serotonin, histamine, and adrenergic pathways; it has no affinity for opioid receptors. So if you’ve heard someone refer to trazodone as a “narcotic,” they’re simply mistaken.
Does trazodone cause weight gain?
It is one of the most-Googled questions about trazodone, and the short answer is: probably not—at least not for most people.
In fact, weight loss is slightly more common than weight gain with trazodone.
Clinical trial data paint a clear picture: approximately 5% of people who take trazodone experience weight gain, while 6% experience weight loss.
The remaining ~89% see no clinically meaningful change in body weight.
Among antidepressants, trazodone is consistently ranked as one of the most weight-neutral options available.
Why are some antidepressants notorious for causing weight gain, while trazodone is not?
The answer lies in receptor pharmacology.
Drugs like mirtazapine and some TCAs powerfully block histamine H1 and serotonin 5-HT2C receptors, which directly stimulate appetite.
Trazodone is a weaker histamine antagonist and antagonizes 5-HT2C receptors, which may suppress appetite.
Additionally, trazodone’s relatively short half-life (5–9 hours for immediate-release formulations) means it clears the system more quickly, potentially limiting the metabolic disruption seen with longer-acting agents.
One study found that patients on trazodone gained an average of just 1.2 pounds over six weeks—a change that was not statistically significant.
However, the study cautioned that weight gain could accumulate over years of use.
The takeaway? If you’re concerned about weight gain when starting an antidepressant, trazodone is one of the safest bets.
But individual responses vary, and any unexplained weight changes should be discussed with your prescriber.
What is trazodone used for?
Trazodone has one FDA-approved indication—major depressive disorder (MDD)—but its real-world use extends far beyond that.
Here’s a breakdown:
| Use | Status | Typical Dose Range |
|---|---|---|
| Major Depressive Disorder | FDA-approved | 150–400 mg/day (divided doses) |
| Insomnia (primary or comorbid) | Off-label | 25–150 mg at bedtime |
| Anxiety disorders | Off-label | 50–200 mg/day |
| PTSD-related nightmares | Guideline-supported off-label | 50–200 mg at bedtime |
| Alzheimer ‘s-related agitation | Off-label | 50–150 mg/day |
| Fibromyalgia (adjunctive) | Off-label | 50–150 mg at bedtime |
| Substance withdrawal | Off-label | Variable |
| Veterinary anxiety (dogs, cats) | Extra-label | 2–8 mg/kg (species-dependent) |
Insomnia: Trazodone is the most commonly prescribed non-benzodiazepine sleep aid in the United States. At low doses (25–100 mg), its potent histamine H1 blockade produces sedation without the tolerance, dependence, or respiratory depression associated with benzodiazepines.
The American Academy of Sleep Medicine (AASM) suggests trazodone for treating nightmares associated with PTSD, and research shows it improves apnea and hypopnea episodes in patients with obstructive sleep apnea without worsening hypoxemia.
PTSD: Trazodone at 50–200 mg has demonstrated efficacy in reducing nightmare frequency and improving overall sleep quality in PTSD patients.
Geriatric care: Trazodone is favored in elderly patients because it lacks anticholinergic effects, does not worsen Parkinsonism, and has minimal cytochrome P450 drug interactions. It also addresses the high prevalence of sleep disturbance and anxiety in this population.
How trazodone works? (mechanism of action)
Trazodone’s mechanism of action is more nuanced than that of a simple SSRI.
It has been characterized as a serotonin antagonist and reuptake inhibitor (SARI), but that label doesn’t fully capture its pharmacology.
At the molecular level, trazodone does three things simultaneously:
Inhibits the serotonin transporter (SERT): This increases extracellular serotonin levels by blocking the reuptake pump that normally clears serotonin from the synaptic cleft. This is the same mechanism used by SSRIs, but trazodone’s inhibition is weaker.
Blocks 5-HT2A and 5-HT2C receptors: This is the “antagonist” part of SARI. By blocking these postsynaptic serotonin receptors, trazodone reduces the anxiety, agitation, and sexual dysfunction that often accompany pure serotonin reuptake inhibition. It also prevents the initial “activation” side effect that makes SSRIs so uncomfortable during the first few weeks.
Blocks histamine H1 receptors: This produces sedation, which is undesirable at antidepressant doses (150–400 mg) but beneficial at low doses (25–100 mg) for insomnia.
Additionally, trazodone blocks α1-adrenergic receptors, which can cause orthostatic hypotension and dizziness.
It has moderate affinity for α2-presynaptic receptors, which may increase noradrenaline release and turnover, contributing to its antidepressant effect.
Unlike TCAs, trazodone has negligible affinity for muscarinic acetylcholine receptors, sparing patients from anticholinergic side effects.
The unique receptor profile produces a drug that enhances serotonin transmission where it’s needed (mood regulation) while dampening it where it causes problems (anxiety, sexual function, sleep architecture).
That is why trazodone is often described as a “gentler” antidepressant—it improves depression without the emotional blunting or anhedonia that some patients report on SSRIs.
What are trazodone side effects?
Trazodone is generally well tolerated, but like all medications, it carries a side effect burden.
Here’s a comprehensive breakdown:
Common side effects (≥5% incidence)
Somnolence/drowsiness: The most common complaint. Occurs in up to 40% of users, particularly at higher doses. Taking the medication at bedtime mitigates this.
Dry mouth: Usually mild.
Dizziness/lightheadedness: Often related to orthostatic hypotension. Rising slowly from sitting or lying positions helps.
Headache: Reported in 10–15% of patients.
Nausea/vomiting: More common at initiation; often resolves within 1–2 weeks.
Constipation: Mild and typically transient.
Serious adverse events (rare but require immediate medical attention)
Priapism: A prolonged, painful erection lasting >4 hours. This is a urological emergency requiring immediate intervention. The incidence is estimated at 1 in 6,000 to 1 in 10,000 male patients. It’s thought to result from α1-adrenergic blockade.
Cardiac arrhythmias (QT prolongation): Trazodone can prolong the QT interval, increasing the risk of torsades de pointes, especially at high doses or when combined with other QT-prolonging drugs.
Serotonin syndrome: A potentially life-threatening condition characterized by agitation, confusion, hyperthermia, tachycardia, and neuromuscular abnormalities. Risk of adverse effects increases when trazodone is combined with other serotonergic agents (SSRIs, SNRIs, MAOIs, triptans, etc.).
Orthostatic hypotension and syncope: More common in elderly patients or those on antihypertensives.
Hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) has been reported, particularly in elderly patients.
Increased bleeding risk: Due to serotonin’s role in platelet aggregation, SSRIs and SARIs like trazodone can increase the risk of gastrointestinal bleeding, especially when combined with NSAIDs, aspirin, or anticoagulants.
Warnings and precautions
Suicidal thoughts and behaviors: Like all antidepressants, trazodone carries a boxed warning for increased risk of suicidal ideation in children, adolescents, and young adults during initial treatment.
Activation of mania/hypomania: Screen for bipolar disorder before initiating treatment.
Discontinuation syndrome: Abrupt cessation may cause anxiety, agitation, and sleep disturbance. A gradual taper is recommended.
Trazodone Dosage and Administration
Dosing trazodone is both an art and a science.
The right dose depends entirely on the indication.
For Major Depressive Disorder (FDA-approved)
Starting dose: 150 mg/day, divided. The most common regimen is 50 mg three times daily after meals.
Titration: Increase by 50 mg/day every 3–4 days based on response and tolerability.
Therapeutic range: 150–400 mg/day. Doses below 150 mg/day are generally not effective for depression because significant SERT occupancy requires higher plasma concentrations.
Maximum dose: 400 mg/day in divided doses for outpatients; up to 600 mg/day for hospitalized inpatients under close monitoring.
Administration: Take with food to reduce gastrointestinal upset and slow absorption, thereby minimizing peak-concentration-related dizziness. If drowsiness is problematic, a larger portion of the daily dose can be taken at bedtime.
For Insomnia (off-label)
Starting dose: 25–50 mg at bedtime. Many patients respond well to 50 mg, which is often prescribed as half of a 100 mg tablet.
Titration: Increase by 25–50 mg every 3–7 days, if needed.
Typical maintenance dose: 50–150 mg at bedtime. The extended-release formulation (Oleptro) is sometimes used at 150–300 mg in patients who wake frequently at night, as it provides more sustained plasma levels.
For Anxiety (off-label)
Starting dose: 50–100 mg/day in divided doses or at bedtime.
Titration: Increase gradually based on response.
Typical maintenance dose: 100–200 mg/day.
Special populations
Elderly: Start at 25–50 mg/day due to increased sensitivity to orthostatic hypotension. Titrate slowly.
Hepatic impairment: Trazodone is extensively metabolized by the liver. Use with caution and consider reduced doses.
Renal impairment: No specific dose adjustment is required, but caution is advised as trazodone is highly protein-bound and clearance may be altered.
Trazodone Precautions and Drug Interactions
Trazodone’s interaction profile is generally cleaner than that of many antidepressants, but several critical interactions demand attention.
MAOIs (Monoamine Oxidase Inhibitors)
Contraindicated. A minimum 14-day washout period is required when switching between trazodone and an MAOI. Concomitant use can precipitate severe serotonin syndrome.
Serotonergic agents
Combining trazodone with SSRIs, SNRIs, triptans, buspirone, fentanyl, lithium, tramadol, tryptophan, or St. John’s wort increases the risk of serotonin syndrome. If combination therapy is clinically necessary, start with low doses and monitor closely.
QT-prolonging drugs
Trazodone can prolong the QT interval. Avoid concomitant use with other QT-prolonging agents (e.g., certain antiarrhythmics, antipsychotics, fluoroquinolone antibiotics, azole antifungals, such as itraconazole, voriconazole) unless the benefit clearly outweighs the risk. ECG monitoring is recommended.
CYP3A4 inhibitors and inducers
CYP3A4 primarily metabolizes trazodone. Potent CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice) can increase trazodone exposure, heightening the risk of adverse effects, including cardiac arrhythmias. CYP3A4 inducers (rifampin, carbamazepine, St. John’s wort) can reduce trazodone efficacy. Dose adjustments may be necessary.
Anticoagulants and antiplatelet agents
Trazodone may increase the risk of bleeding when used with warfarin, heparin, aspirin, NSAIDs, clopidogrel, or other drugs that affect coagulation. Educate patients about signs of bleeding (easy bruising, black stools, prolonged bleeding from cuts).
Alcohol and CNS depressants
Trazodone enhances the sedative effects of alcohol, benzodiazepines, opioids, antihistamines, and other CNS depressants. Advise patients to avoid alcohol and use caution when driving or operating machinery until they understand how trazodone affects them.
Pregnancy and lactation
Trazodone is pregnancy category C (risk cannot be ruled out). Animal studies have shown increased fetal resorption at doses 7–11 times the maximum recommended human dose, though no teratogenic effects were observed in rats and rabbits at high oral doses. Trazodone is excreted in breast milk; the decision to breastfeed while taking trazodone should weigh the developmental benefits of breastfeeding against the potential risks.
Trazodone vs. Other Medications
How does trazodone stack up against other commonly prescribed drugs?
Let’s go head-to-head.
| Drug | Class | Primary Use | Sedation | Weight Gain | Sexual Dysfunction | Abuse Potential |
|---|---|---|---|---|---|---|
| Trazodone | SARI | Depression, insomnia | High (low dose) | Low | Low | Low |
| Sertraline (Zoloft) | SSRI | Depression, anxiety | Low | Moderate | Moderate | Low |
| Fluoxetine (Prozac) | SSRI | Depression, OCD | Low | Low (short-term), gain (long-term) | High | Low |
| Venlafaxine (Effexor) | SNRI | Depression, anxiety | Low | Low | High | Low |
| Mirtazapine (Remeron) | NaSSA | Depression | High | High | Low | Low |
| Amitriptyline | TCA | Depression, pain | High | High | Moderate | Low |
| Zolpidem (Ambien) | Z-drug | Insomnia | High | No data | None | Moderate |
| Benzodiazepines | GABA-A agonist | Anxiety, insomnia | High | No data | Low | High |
Trazodone’s key differentiator is its safety profile. It does not carry the abuse liability of benzodiazepines or Z-drugs, the weight gain of mirtazapine or TCAs, or the sexual dysfunction of SSRIs and SNRIs.
For patients who need both antidepressant efficacy and help with sleep—without the baggage of addiction potential—trazodone is often the ideal choice.
Is trazodone safe during pregnancy?
The answer is nuanced. A 2025 systematic review published in the European Journal of Clinical Pharmacology examined 14 studies on trazodone exposure during pregnancy.
The review found no consistent evidence linking trazodone to congenital malformations, stillbirths, or low birth weight.
However, some studies suggested a possible association with an increased risk of spontaneous and therapeutic abortions.
Multiple studies have found no increase in miscarriage risk when trazodone is taken during pregnancy. However, one study noted an increased chance of miscarriage after antidepressant exposure in the first trimester.
Neonatal adaptation syndrome—temporary symptoms such as jitteriness, feeding difficulties, and respiratory distress—has been reported in newborns exposed to antidepressants (including trazodone) late in the third trimester.
The FDA has not assigned trazodone a formal pregnancy category under the new Pregnancy and Lactation Labeling Rule (PLLR).
The official guidance is that trazodone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. That use should be avoided during the first trimester if possible.
For women who are pregnant or planning to become pregnant, the decision to continue or discontinue trazodone should be made collaboratively with a psychiatrist and obstetrician, weighing the risks of untreated depression against the potential risks of medication exposure.
How long does trazodone take to work?
The timeline depends on what you’re treating:
For sleep (sedative effect): Trazodone’s sedating properties kick in rapidly—usually within 30–60 minutes of taking an immediate-release dose. This is why it’s so effective as a sleep aid: the histamine H1 blockade produces drowsiness that coincides with bedtime when the medication is taken on an empty stomach 30 minutes before sleep.
For depression (antidepressant effect): Trazodone may begin to relieve depressive symptoms within 1–2 weeks of starting treatment, but the full therapeutic effect typically takes 4–6 weeks to manifest. Some patients may need up to 8 weeks to experience maximum benefit. This delayed onset is common to all antidepressants and reflects the time required for neuroplastic changes (receptor downregulation, increased BDNF expression) rather than the acute pharmacological effects.
For anxiety: Improvement in anxiety symptoms often parallels the antidepressant timeline (2–4 weeks), though some patients report early relief due to trazodone’s calming effects.
A common pitfall: patients who feel sedated but not less depressed after the first week may assume the medication isn’t working.
This is a mistake. Its sedative effect is immediate, while its antidepressant effect is not. Patience is essential.
How long does trazodone last?
Trazodone’s pharmacokinetic profile explains its duration of action:
Half-life (immediate-release): 5–9 hours, with an average of approximately 7 hours.
Half-life (extended-release/Oleptro): 10–13 hours, owing to the controlled-release matrix that slows absorption.
Active metabolite: m-Chlorophenylpiperazine (m-CPP) has a half-life of approximately 4–7 hours and may contribute to trazodone’s serotonergic effects, though its clinical significance is debated.
In practical terms, after a single dose in a healthy adult, trazodone is largely eliminated from the body within 1–3 days (approximately 5 half-lives).
Urine drug screens are not standardly designed to detect trazodone, but specialized tests can identify it for up to 2–4 days after the last dose.
For patients using trazodone for insomnia, the medication’s relatively short half-life is an advantage: it’s typically out of the system by morning, reducing the risk of daytime grogginess.
The extended-release formulation is designed to sustain plasma levels through the night for patients who struggle with sleep maintenance (waking up at 3 a.m.) rather than sleep initiation.
Is there trazodone for dogs?
Yes—trazodone is widely used in veterinary medicine, though it is not FDA-approved for animals.
Veterinarians prescribe it as an extra-label drug, which is a legal and routine practice in veterinary care when no approved veterinary product exists.
Veterinary indications
Situational anxiety: Fireworks, thunderstorms, vet visits, travel, grooming appointments
Separation anxiety: When combined with behavior modification training
Post-operative confinement: Keeps dogs calm during restricted activity periods
Generalized anxiety: As part of a multi-modal treatment plan
Aggression: Adjunctive therapy to reduce reactivity
Typical dosage for dogs
General anxiety (daily use): 2–8 mg/kg orally every 8–24 hours
Situational anxiety (as-needed): 5–7 mg/kg given 1–2 hours before the stressful event
Post-operative confinement: 3.5 mg/kg starting dose, titrated up to 7–10 mg/kg for a minimum of four weeks
Important: Extended-release (ER) tablets are generally not recommended for pets because they cannot be easily split or adjusted to appropriate doses.
Is trazodone safe for cats?
Yes, though use in cats is less common and doses are typically lower.
Cats metabolize drugs differently, so a veterinarian must carefully determine the appropriate dose.
Trazodone has been studied for reducing transport- and examination-related anxiety in cats.
How long does trazodone last in dogs?
The pharmacokinetics of trazodone in dogs differ from those in humans.
After oral administration, trazodone reaches peak plasma concentrations in dogs in approximately 1–2 hours.
The elimination half-life in canines ranges from approximately 3–6 hours, which is shorter than in humans (5–9 hours).
It means that the sedative/anxiolytic effects of a single dose typically last 4–8 hours in most dogs, though individual variation is significant.
For situational anxiety (e.g., a vet visit), the recommended protocol is to administer trazodone 1–2 hours before the stressful event to ensure peak plasma levels coincide with the trigger.
For chronic anxiety management, twice-daily or three-times-daily dosing may be necessary to maintain therapeutic levels throughout the day.
Veterinary research published in 2024 recommends a dose range of 1–16 mg/kg every 24 hours for single-daily dosing, or 1–19 mg/kg every 24 hours when combined with other anxiolytics.
Trazodone vs. Other Antidepressants
Let’s expand the comparison table from earlier with clinical nuance.
| Drug | Class | Mechanism | Onset of Action | Key Advantages | Key Disadvantages |
|---|---|---|---|---|---|
| Trazodone | SARI | SERT inhibition + 5-HT2A/2C antagonism + H1 blockade | 1–2 weeks (sedation within 1 hour) | No sexual dysfunction, weight-neutral, non-addictive, dual action on depression and insomnia | Sedation at therapeutic doses, orthostatic hypotension, and priapism risk (rare) |
| Sertraline | SSRI | Selective SERT inhibition | 2–4 weeks | Robust efficacy data, FDA-approved for multiple anxiety disorders, and generally well-tolerated | Sexual dysfunction (30–50% of patients), GI distress, activation/agitation early in treatment |
| Venlafaxine | SNRI | SERT + NET inhibition (dose-dependent) | 2–4 weeks | Potent antidepressant, effective for treatment-resistant depression at higher doses | Nausea, hypertension, severe discontinuation syndrome, and sexual dysfunction |
| Mirtazapine | NaSSA | α2-antagonist (increases NE and 5-HT) + H1/5-HT2/5-HT3 blockade | 1–2 weeks (sedation within 30 min) | Rapid onset, improves sleep and appetite, and has low sexual dysfunction | Significant weight gain (5–15 lbs typical), daytime sedation |
| Bupropion | NDRI | NET + DAT inhibition | 2–4 weeks | No sexual dysfunction, no weight gain, energizing, smoking cessation aid | No anti-anxiety benefit, lowers seizure threshold, causes insomnia, and agitation |
| Vortioxetine | Multimodal | SERT inhibition + 5-HT receptor modulation | 2–4 weeks | Cognitive benefits, flexible receptor profile, weight-neutral | Nausea (common), expensive (brand-only until recently), limited long-term data vs. SSRIs |
| Amitriptyline | TCA | SERT + NET inhibition + multiple receptor blockade | 2–4 weeks | Highly effective for severe depression, excellent for neuropathic pain and migraine prophylaxis | Anticholinergic burden, cardiotoxicity in overdose, weight gain, sedation, and lethality in overdose |
Key study: Trazodone XR vs SSRIs head-to-head
A 2025 original research article in Frontiers in Pharmacology compared trazodone extended-release (XR) to SSRIs in 180 patients over 12 weeks.
The results were striking: both trazodone XR and SSRIs improved health status and quality of life, but trazodone XR provided greater improvements in self-care, usual activities, pain/discomfort, and anxiety/depression measures.
Trazodone XR patients also showed a trend toward higher remission rates and more sustained antidepressant response over time. Importantly, the proportion of patients experiencing “mixed changes” (some improvements, some worsening) was higher in the SSRI group, suggesting trazodone XR provides a more consistent trajectory of improvement.
The study reinforces what many clinicians have observed in practice: trazodone is not a second-tier antidepressant.
It is a first-line contender, especially for patients with comorbid insomnia, anxiety, or concerns about sexual side effects.
Compounding Guidelines for Trazodone Hydrochloride
Compounding pharmacists frequently prepare customized trazodone formulations for patients who cannot take commercially available tablets—such as pediatric patients, elderly patients with swallowing difficulties, patients requiring non-standard doses, or those with allergies to inactive ingredients.
Key considerations for compounding trazodone hydrochloride
Trazodone API source quality: Use only USP-grade trazodone hydrochloride. The USP monograph specifies an assay range of 97.0–102.0% (C₁₉H₂₂ClN₅O·HCl, calculated on a dried-basis). Sourcing from reputable suppliers like PCCA ensures consistent purity.
Physical properties of the API: Trazodone hydrochloride USP is a white to off-white crystalline powder with a melting point of 207–253°C and a pH of 3.9–4.5 in solution. It is sparingly soluble in water, a fact that must be accounted for when designing liquid formulations.
Common compounded preparations:
Trazodone Hydrochloride 10 mg/mL Oral Liquid: A well-established formulation published in the International Journal of Pharmaceutical Compounding includes the API, a suspending vehicle, a sweetening agent, and a preservative system. The method involves levigating the powder with a small amount of vehicle, gradually incorporating the remainder of the vehicle, and storing the resulting mixture in amber bottles under refrigeration.
Trazodone Hydrochloride 50 mg/5 mL Sugar-Free Oral Solution: Commercially available in some countries as a reference for extemporaneous compounding.
Capsule formulations: For patients requiring doses not commercially available (e.g., 75 mg), pharmacists can compound capsules using geometric dilution with a suitable filler, such as microcrystalline cellulose.
Stability considerations: Trazodone hydrochloride is sensitive to light and moisture. Compounded preparations should be stored in tight, light-resistant containers. Aqueous solutions should be refrigerated (2–8°C) and assigned a conservative beyond-use date unless stability data support a longer period.
Regulatory compliance: In the United States, compounding must comply with USP <795> (non-sterile preparations), USP <800> (hazardous drug handling), and applicable state board of pharmacy regulations. The FDA’s guidance on pharmacy compounding (Sections 503A and 503B of the FD&C Act) distinguishes between traditional compounding and large-scale outsourcing facilities.
Safety warnings for compounded preparations: The PCCA label specifies that trazodone hydrochloride USP must undergo further processing when preparing injectable dosage forms to ensure acceptable levels of bacterial endotoxins. For prescription compounding, the product is Rx-only.
Conclusion
Trazodone occupies a unique niche in psychopharmacology.
It is simultaneously a legitimate antidepressant, a first-line non-addictive sleep aid, and a safe anxiolytic for veterinary patients.
Its receptor profile—SERT inhibition balanced by 5-HT2A/2C antagonism—delivers antidepressant efficacy without the sexual dysfunction, weight gain, or emotional blunting that drive non-adherence with SSRIs and SNRIs.
And for patients with comorbid insomnia, its rapid-onset sedation (non-addictive, non-GABAergic) is arguably its greatest strength.
At the same time, trazodone is not without risks. Priapism, orthostatic hypotension, QT prolongation, and serotonin syndrome are rare but serious adverse events that demand respect.
Drug interactions with MAOIs, CYP3A4 inhibitors, and serotonergic agents require careful medication reconciliation. In pregnancy, the evidence for safety is reassuring but incomplete—a shared decision-making approach is essential.
For compounding pharmacists, trazodone hydrochloride USP offers flexibility to meet individual patient needs, from oral liquids to custom-dose capsules, provided that quality, stability, and regulatory standards are maintained.
And for Trazodone API procurement professionals, the global market for trazodone HCl API exemplifies the rigorous standards—including GMP compliance, pharmacopoeial conformity, regulatory documentation, and supply chain resilience—that define modern pharmaceutical sourcing.
Whether you’re a clinician prescribing trazodone for a depressed patient who hasn’t slept in months, a pharmacist preparing a customized dose for an elderly patient, or a procurement specialist vetting an API supplier, the principles are the same: quality, evidence, and patient-centered care.
Trazodone has been part of the pharmacopeia since 1981—and its story is far from over.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
